Automated synthesis of 68Ga/177Lu-PSMA on the Trasis miniAllinOne
Research output: Contribution to journal › Journal article › Research › peer-review
Prostate-specific membrane antigen (PSMA)-based radioligands for positron emission tomography (PET)/computed tomography (CT) studies represent the gold standard for detection of recurrent prostate cancer (PCa). [68Ga]PSMA-HBED-CC is a PET radiotracer suitable for detection of PCa, and its clinical use has become widespread over the last few years. In this contribution, we detail our GMP-compliant production of [68Ga]PSMA-HBED-CC using the Trasis miniAllinOne radiosynthesizer and report synthetic and clinical data for the first 100 productions of 2019. Additionally, we detail our efforts towards a GMP-compliant production of the radiotherapeutic [177Lu]PSMA-I&T using the same synthesis module. PSMA-based radioligand therapy (RLT) offers a possible future treatment in cases of metastatic castration-resistant PCa, and GMP-compliant routine production methods are therefore called for. This report highlights how PSMA-based agents for theranostic purposes can be conveniently produced at a single radiochemistry Good Manufacturing Practice (GMP) site, thereby facilitating optimized detection and treatment of PCa.
Original language | English |
---|---|
Journal | Journal of Labelled Compounds and Radiopharmaceuticals |
Volume | 63 |
Issue number | 8 |
Pages (from-to) | 393-403 |
Number of pages | 11 |
ISSN | 0362-4803 |
DOIs | |
Publication status | Published - 2020 |
- GMP, PET/CT, prostate cancer, PSMA, [Lu]PSMA-I&T, [Ga]PSMA-HBED-CC
Research areas
ID: 260203758